Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/annual-reviews/nsaids-and-cancer-prevention-targets-downstream-of-cox-2-aVgvUD3Eo5
References
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
- Publisher
- Annual Reviews
- Copyright
- Copyright © 2007 by Annual Reviews. All rights reserved
- ISSN
- 0066-4219
- eISSN
- 1545-326X
- DOI
- 10.1146/annurev.med.57.121304.131253
- pmid
- 17100552
- Publisher site
- See Article on Publisher Site
Abstract
Abstract Preclinical and clinical studies have clearly shown a benefit of nonsteroidal anti-inflammatory drug (NSAID) use in reducing cancer risk. However, the adverse gastrointestinal and cardiovascular side effects associated with NSAIDs and COX-2 selective inhibitors (coxibs) have provoked more scrutiny of the precise role of specific downstream mediators in the prostaglandin (PG) signaling cascade. NSAIDs and coxibs inhibit PG biosynthesis. One of the PGs produced at high levels in the tumor microenvironment is PGE 2 , which is thought to play a major role in cancer progression. Thus, a better understanding of PGE 2 signaling could enable identification of novel and safer therapeutic targets downstream of the cyclooxygenase enzymes. We review the emerging molecular mechanisms by which COX-2–derived PGE 2 is involved in cancer progression and delineate potential opportunities for development of novel pharmacologic approaches utilizing this pathway.
Journal
Annual Review of Medicine – Annual Reviews
Published: Feb 18, 2007